[Form 4] Aurinia Pharmaceuticals Inc. Insider Trading Activity

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. (AUPH) reported an insider equity transaction on a Form 4 involving one director. On 11/21/2025, the director had 6,039 common shares withheld at a price of $15.68 per share to cover tax withholding obligations tied to the vesting of restricted stock units. After this tax-related withholding, the director directly beneficially owned 14,592 common shares of Aurinia. This event reflects routine equity compensation and tax management rather than an open-market purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Johnson Craig A

(Last) (First) (Middle)

#140, 14315 - 118 AVENUE

(Street)

EDMONTON A0 T5L 4S6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/21/2025		F		6,039(1)	D	$15.68	14,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

Remarks:

	/s/ Craig Johnson	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aurinia Pharmaceuticals (AUPH) report on this Form 4?

Aurinia Pharmaceuticals reported that a director had 6,039 common shares withheld on 11/21/2025 to satisfy tax withholding obligations from vesting restricted stock units.

How many Aurinia (AUPH) shares does the director own after this transaction?

Following the reported tax withholding transaction, the director directly beneficially owned 14,592 common shares of Aurinia Pharmaceuticals Inc.

What was the price per Aurinia (AUPH) share used for tax withholding?

The shares withheld to cover taxes were valued at a price of $15.68 per Aurinia common share.

Was this Aurinia (AUPH) Form 4 transaction an open-market sale or purchase?

No. The Form 4 states that the 6,039 shares represent shares withheld to satisfy tax withholding obligations upon vesting of restricted stock units, not an open-market trade.

What is the reporting person’s relationship to Aurinia Pharmaceuticals (AUPH)?

The reporting person on this Form 4 is identified as a Director of Aurinia Pharmaceuticals Inc.

Does this Aurinia (AUPH) Form 4 indicate joint filing by multiple insiders?

No. The filing indicates that the Form is filed by one reporting person, not by more than one reporting person.